These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21762075)

  • 41. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
    Wang W; Takimoto R; Rastinejad F; El-Deiry WS
    Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
    Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
    Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
    Dickens MP; Fitzgerald R; Fischer PM
    Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
    Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS
    J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
    Wang W; Hu Y
    Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
    Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
    Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2.
    He Y; Tollini L; Kim TH; Itahana Y; Zhang Y
    Cell Cycle; 2014; 13(13):2101-9. PubMed ID: 24804778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon?
    Macchiarulo A; Giacchè N; Mancini F; Puxeddu E; Moretti F; Pellicciari R
    Expert Opin Ther Pat; 2011 Mar; 21(3):287-94. PubMed ID: 21342053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
    Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery.
    Auger KR; Copeland RA; Lai Z
    Methods Enzymol; 2005; 399():701-17. PubMed ID: 16338390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MDM2 inhibition: an important step forward in cancer therapy.
    Konopleva M; Martinelli G; Daver N; Papayannidis C; Wei A; Higgins B; Ott M; Mascarenhas J; Andreeff M
    Leukemia; 2020 Nov; 34(11):2858-2874. PubMed ID: 32651541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells.
    Putri HE; Nutho B; Rungrotmongkol T; Sritularak B; Vinayanuwattikun C; Chanvorachote P
    Phytomedicine; 2021 May; 85():153534. PubMed ID: 33773191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
    Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
    Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
    Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
    Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
    Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
    Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
    Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.